0402 AACR 2021

Product Development

Digging beyond the headlines at AACR 2021 

Next-wave strategies for KRAS and TIGIT, allogeneic and personalized cell therapies, and targeted protein degraders

Next-wave strategies for KRAS and TIGIT, allogeneic and personalized cell therapies, and targeted protein degraders.

Apr 3, 2021 | 3:43 AM GMT

BioCentury’s analysis of this year’s AACR meeting unearths orthogonal approaches to high-wattage targets KRAS and TIGIT, details on allogeneic and personalized cell therapies, and targeted protein degradation players beyond the usual suspects.

In the run-up to the 2021 virtual meeting of the American Association for Cancer research (AACR), all eyes are on publicly traded companies teasing clinical data for hot targets and modalities via embargoed presentations. But published abstracts provide a window further into the future, with insights into how companies with earlier-stage programs are seeking differentiated takes on similar themes.

For the highly watched, once “undruggable” target KRAS, AACR brings early data for at least 10 compounds, as well

Read the full 1548 word article

How to gain access

Continue reading with a
two-week free trial.